NovaBridge Biosciences - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US44975P1030
1,53 € ↑0,07 (4,79%)
2026-06-05
DEL PRIS
SecurityDE:0VY / NovaBridge Biosciences - Depositary Receipt (Common Stock)
InstitutionGoldman Sachs Group Inc
Latest Disclosed Ownership112,463 shares
Latest Disclosed Value $ 276,659
Goldman Sachs Group Inc reports 20.21% decrease in ownership of 0VY / NovaBridge Biosciences - Depositary Receipt (Common Stock)

On May 15, 2026 - Goldman Sachs Group Inc filed a 13F-HR form disclosing ownership of 112,463 shares of NovaBridge Biosciences - Depositary Receipt (Common Stock) (DE:0VY) valued at $217,054 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 140,946 shares of NovaBridge Biosciences - Depositary Receipt (Common Stock). This represents a change in shares of -20.21% during the quarter. The current value of the position is $172,068 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NOVABRIDGE BIOSCIENCES CMN 44975P103 112,463 -28,483 -20.21 277 -50.71 0.0000
2026-02-10 2025-12-31 13F NOVABRIDGE BIOSCIENCES CMN 44975P103 140,946 -77,524 -35.48 561 -32.12 0.0001
2025-11-14 2025-09-30 13F I MAB CMN 44975P103 218,470 207,788 1,945.22 826 3,200.00 0.0001
2025-08-14 2025-06-30 13F I MAB CMN 44975P103 10,682 -3 -0.03 26 212.50 0.0000
2025-06-27 2025-03-31 13F/A-2 I MAB CMN 44975P103 10,685 0 0.00 9 -11.11 0.0000
2025-05-16 2025-03-31 13F/A-1 I MAB CMN 44975P103 10,685 0 9 0.0000
2025-05-09 2025-03-31 13F I MAB CMN 44975P103 10,685 0 9 0.0000
2025-02-11 2024-12-31 13F I MAB CMN 44975P103 10,685 0 0.00 9 -30.77 0.0000
2024-11-14 2024-09-30 13F I MAB CMN 44975P103 10,685 -5,065 -32.16 13 -50.00 0.0000
2024-08-13 2024-06-30 13F I MAB CMN 44975P103 15,750 -69,191 -81.46 26 -83.44 0.0000
2024-05-15 2024-03-31 13F I MAB CMN 44975P103 84,941 -60,254 -41.50 158 -42.91 0.0000
2024-05-14 2023-12-31 13F/A-2 I MAB CMN 44975P103 145,195 -96,176 -39.85 276 -13.52 0.0001
2024-03-01 2023-12-31 13F/A-1 I MAB CMN 44975P103 145,195 -96,176 276 0.0000
2024-02-13 2023-12-31 13F I MAB CMN 44975P103 145,195 -96,176 276 0.0000
2024-05-15 2023-09-30 13F/A-1 I MAB CMN 44975P103 241,371 -53,162 -18.05 319 -63.86 0.0001
2023-11-14 2023-09-30 13F I MAB CMN 44975P103 241,371 -53,162 319 0.0001
2024-05-14 2023-06-30 13F/A-1 I MAB CMN 44975P103 294,533 -64,587 -17.98 881 -29.15 0.0002
2023-08-15 2023-06-30 13F I MAB CMN 44975P103 294,533 -64,587 881 0.0002
2024-05-14 2023-03-31 13F/A-1 I MAB CMN 44975P103 359,120 -173,360 -32.56 1,243 -44.18 0.0003
2023-05-11 2023-03-31 13F I MAB CMN 44975P103 359,120 -173,360 1,243 0.0003
2024-05-14 2022-12-31 13F/A-1 I MAB CMN 44975P103 532,480 -605,858 -53.22 2,226 55,525.00 0.0005
2023-02-13 2022-12-31 13F I MAB CMN 44975P103 532,480 -605,858 2,226 0.0005
2024-05-14 2022-09-30 13F/A-1 I MAB CMN 44975P103 1,138,338 59,143 5.48 5 -66.67 0.0012
2022-11-14 2022-09-30 13F I MAB CMN 44975P103 1,138,338 59,143 4,565 0.0011
2024-05-14 2022-06-30 13F/A-2 I MAB CMN 44975P103 1,079,195 352,503 48.51 12 -99.90 0.0030
2022-08-18 2022-06-30 13F/A-1 I MAB CMN 44975P103 1,079,195 352,503 12,195 0.0028
2022-08-15 2022-06-30 13F I MAB CMN 44975P103 1,079,195 352,503 12,195 0.0008
2022-05-16 2022-03-31 13F I MAB CMN 44975P103 726,692 360,273 98.32 11,801 -32.04 0.0025
2022-02-17 2021-12-31 13F/A-1 I MAB CMN 44975P103 366,419 155,858 74.02 17,365 13.76 0.0034
2022-02-14 2021-12-31 13F I MAB CMN 44975P103 366,419 155,858 17,365 0.0010
2022-01-20 2021-09-30 13F/A-1 I MAB CMN 44975P103 210,561 69,489 49.26 15,264 28.89 0.0032
2021-11-10 2021-09-30 13F I MAB CMN 44975P103 210,561 69,489 15,264 0.0009
2021-08-13 2021-06-30 13F I MAB CMN 44975P103 141,072 -7,530 -5.07 11,843 64.42 0.0027
2021-05-17 2021-03-31 13F I MAB CMN 44975P103 148,602 132,595 828.36 7,203 854.04 0.0018
2021-02-12 2020-12-31 13F I MAB CMN 44975P103 16,007 -40,899 -71.87 755 -71.79 0.0002
2020-11-13 2020-09-30 13F I MAB CMN 44975P103 56,906 56,906 2,676 0.0008
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.